Language

English

Publication Date

10-1-2024

Journal

International Journal of Hematology

DOI

10.1007/s12185-024-03789-x

PMID

38750343

PMCID

PMC11779507

PubMedCentral® Posted Date

1-29-2025

PubMedCentral® Full Text Version

Author MSS

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy primarily driven by an immature population of AML cells termed leukemia stem cells (LSCs) that are implicated in AML development, chemoresistance, and relapse. An emerging area of research in AML focuses on identifying and targeting the aberrant metabolism in LSCs. Dysregulated metabolism is involved in sustaining functional properties of LSCs, impeding myeloid differentiation, and evading programmed cell death, both in the process of leukemogenesis and in response to chemotherapy. This review discusses recent discoveries regarding the aberrant metabolic processes of AML LSCs that have begun to change the therapeutic landscape of AML.

Keywords

Humans, Leukemia, Myeloid, Acute, Neoplastic Stem Cells, Animals, Cell Differentiation, Drug Resistance, Neoplasm, acute myeloid leukemia, leukemia stem cell, metabolic regulation

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.